1. Home
  2. /
  3. Projects
  4. /
    5. Page 3

Ongoing

FAST-TB MOD

2023-2026
Hypothetical vaccine
Ongoing
FAST-TB population and cost-effectiveness modelling core: This project will accelerate tuberculosis (TB) research translation by using mathematical modelling to address key priority questions as part of FAST TB, linking an expanded state-of-the-art modelling framework with country level data and cross consortium communication around new TB treatment regimens, diagnostics and other interventions.

Preparing the landscape for TB vaccines: South Africa’s strategic planning

Ongoing
The South African TB Think Tank is a national collaboration of TB stakeholders, including researchers, policymakers, clinicians, and civil society. Chaired by the Chief Director of the National TB Programme (NTP), members consolidate TB research through several technical task teams, providing evidenced-based policy recommendations to the Department of Health. To support the national TB vaccine initiative, the TB Think Tank provided recommendations for the recently released NTP Strategic Plan, 2023-28

Creating evidence to support tuberculosis (TB) national and global decision-makers in reducing the global burden of TB

2024-2028
Hypothetical vaccine
Ongoing
In strong collaboration, we (India, South Africa, Brazil, Indonesia, UK) will create evidence to strengthen capacity and sustainably support high tuberculosis (TB) burden countries (HBC) and global decision-makers in reducing the global burden of TB, by using modelling tools to address key questions on drug-resistant (DR-)TB, new TB vaccines and other interventions, and extend and apply a state-of-the-art TB model, to estimate the relative health, cost-effectiveness, and budget impact, of new and existing interventions, as well as their optimal combination.

Forecasting TB vaccine demand to support supply and procurement planning

Ongoing
We present insights from two workshops with global health funders, academics, and in country TB and vaccine decision-makers and estimates of potential global demand for TB vaccines using a bottom-up, constrained demand forecasting model. The model was informed by the workshops, publicly available target product profile, landscape assessment of vaccines in development, information from proxy vaccines sourced from the WHO databases and peer reviewed literature, and interviews with TB and vaccine experts

Global TB vaccine partnership

2011-2023
Ongoing
The Global Tuberculosis Vaccine Partnership (GTBVP) is a forum for key stakeholders in TB vaccine R&D to identify and address barriers impeding TB vaccine R&D and to discuss R&D priorities in order to help inform funding decisions

Epidemiologic study to assess the IGRA positivity in populations with a high TB

2021 - 2024
M72/AS01e
Ongoing
Tuberculosis (TB) vaccine efficacy trials evaluating prevention of disease must be feasible in size and duration and would ideally take place at clinical trial sites that enroll from communities with the highest incidence rates. In preparation for the Phase 3 trial of the investigational M72/AS01E-4 vaccine, we conducted a multi-country study, using interferon gamma release assay (IGRA) positivity as a proxy for expected incidence of TB. In addition to the above objects, the results from this study could help in in new vaccine introduction to identfy TB hotspot areas.

TB vaccine advocacy roadmap

2021
Ongoing
The TB Vax ARM represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research, and seeks to provide coordinated advocacy efforts that are complementary to ongoing TB vaccine R&D and policy efforts. The TB Vax ARM holds regular virtual calls with partners and guest speakers from around the world. WGNV coordinates with the TB Vax ARM on global advocacy activities. For more information go to: https://newtbvaccines.org/take-action/
Load More
Click to copy link of this header Menu